BRPI0519209A2 - compostos orgçnicos - Google Patents

compostos orgçnicos

Info

Publication number
BRPI0519209A2
BRPI0519209A2 BRPI0519209-9A BRPI0519209A BRPI0519209A2 BR PI0519209 A2 BRPI0519209 A2 BR PI0519209A2 BR PI0519209 A BRPI0519209 A BR PI0519209A BR PI0519209 A2 BRPI0519209 A2 BR PI0519209A2
Authority
BR
Brazil
Prior art keywords
mono
organic compounds
diaspartate
diglutamate
disuccinate
Prior art date
Application number
BRPI0519209-9A
Other languages
English (en)
Inventor
Olivier Lambert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0519209A2 publication Critical patent/BRPI0519209A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

COMPOSTOS ORGÂNICOS. A presente invenção refere-se a uma composição farmacêutica para administração parenteral de um sal de um análogo de somatostatina, aspartato, como por exemplo, mono ou diaspartato, lactato, succinato, como por exemplo, mono ou dissuccinato, acetato, glutamato, como por exemplo, mono ou diglutamato, ou citrato, e água, formando um sistema de depósito geleificante, após injeção em contato com um fluido corporal.
BRPI0519209-9A 2004-12-22 2005-12-20 compostos orgçnicos BRPI0519209A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428151.5A GB0428151D0 (en) 2004-12-22 2004-12-22 Organic compounds
PCT/EP2005/013703 WO2006066868A2 (en) 2004-12-22 2005-12-20 Sustained release formulation comprising bisphosphonate

Publications (1)

Publication Number Publication Date
BRPI0519209A2 true BRPI0519209A2 (pt) 2009-01-06

Family

ID=34113101

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519209-9A BRPI0519209A2 (pt) 2004-12-22 2005-12-20 compostos orgçnicos

Country Status (19)

Country Link
US (2) US20100029550A1 (pt)
EP (1) EP1830806B1 (pt)
JP (1) JP4977622B2 (pt)
KR (1) KR101335757B1 (pt)
CN (1) CN101072551B (pt)
AR (1) AR051803A1 (pt)
AU (1) AU2005318454B2 (pt)
BR (1) BRPI0519209A2 (pt)
CA (1) CA2585116C (pt)
ES (1) ES2515097T3 (pt)
GB (1) GB0428151D0 (pt)
GT (1) GT200500358A (pt)
MX (1) MX2007007572A (pt)
PE (1) PE20060769A1 (pt)
PL (1) PL1830806T3 (pt)
PT (1) PT1830806E (pt)
RU (1) RU2395274C2 (pt)
TW (1) TW200637612A (pt)
WO (1) WO2006066868A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
JP5331817B2 (ja) 2007-12-03 2013-10-30 イタルファルマコ ソシエタ ペル アチオニ 新規な非選択的ソマトスタチン類似体
EP2067786A1 (en) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Novel non selective analogs of somatostatin
PT2523653T (pt) 2010-01-13 2018-06-28 Ipsen Pharma Sas Processo para a preparação de composições farmacêuticas para a libertação prolongada de análogos de somatostatina
US8535544B2 (en) 2010-07-26 2013-09-17 International Business Machines Corporation Structure and method to form nanopore
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
WO2018048609A1 (en) * 2016-09-06 2018-03-15 Monell Chemical Senses Center Method of regulating immunity in the intestines
CN110475558A (zh) * 2017-03-09 2019-11-19 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂在儿茶酚胺分泌型肿瘤治疗中的应用
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
CN118302211A (zh) * 2021-11-22 2024-07-05 Specgx有限责任公司 可注射缓释药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE14226T1 (de) * 1981-12-24 1985-07-15 Ciba Geigy Ag Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung.
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
ES2158611T3 (es) 1996-12-20 2001-09-01 Alza Corp Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion.
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP1480618B1 (en) * 2002-03-04 2009-06-03 Ipsen Pharma Sustained release drug formulations containing a carrier peptide
GB0300095D0 (en) 2003-01-03 2003-02-05 Novartis Ag Organic compounds
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
PL2310042T3 (pl) * 2008-07-08 2013-05-31 Novartis Ag Zastosowanie pasyreotydu do leczenia endogennej hipoglikemii hiperinsulinemicznej

Also Published As

Publication number Publication date
WO2006066868A3 (en) 2006-10-12
PT1830806E (pt) 2014-11-24
US20150038414A1 (en) 2015-02-05
GT200500358A (es) 2006-08-07
EP1830806B1 (en) 2014-09-03
CN101072551A (zh) 2007-11-14
PE20060769A1 (es) 2006-09-28
AR051803A1 (es) 2007-02-07
GB0428151D0 (en) 2005-01-26
CN101072551B (zh) 2013-04-24
US9303067B2 (en) 2016-04-05
EP1830806A2 (en) 2007-09-12
CA2585116A1 (en) 2006-06-29
AU2005318454B2 (en) 2009-08-20
KR20070090942A (ko) 2007-09-06
RU2007128101A (ru) 2009-01-27
US20100029550A1 (en) 2010-02-04
JP4977622B2 (ja) 2012-07-18
WO2006066868A2 (en) 2006-06-29
CA2585116C (en) 2014-05-20
MX2007007572A (es) 2007-07-24
JP2008524290A (ja) 2008-07-10
KR101335757B1 (ko) 2013-12-02
RU2395274C2 (ru) 2010-07-27
AU2005318454A1 (en) 2006-06-29
TW200637612A (en) 2006-11-01
PL1830806T3 (pl) 2015-03-31
ES2515097T3 (es) 2014-10-29

Similar Documents

Publication Publication Date Title
BRPI0519209A2 (pt) compostos orgçnicos
PE20130589A1 (es) Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
MX338338B (es) Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias.
ECSP066477A (es) Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
NZ597237A (en) Sublingual apomorphine
MX2010007523A (es) Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
NZ607595A (en) A process for concentration of a polypeptide
TNSN07419A1 (en) Methods for treating drug resistant cancer
RS51688B (en) METHOTREXATE CONCENTRATED SOLUTIONS
SG162744A1 (en) Stable active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
WO2006131923A3 (en) Novel salts of conjugated psychotropic drugs and processes of preparing same
DE60116483D1 (de) Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
MX2007009312A (es) Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables.
RS53408B (en) PHARMACEUTICAL COMPOSITION OF IBUPROFEN FOR INJECTION
WO2008001204A3 (en) Transdermal compositions of pramipexole having enhanced permeation properties
BR112013016554A2 (pt) métodos e composições úteis para promover sono nos animais
BRPI0800744A2 (pt) composiÇço de inibiÇço de infecÇço por salmonella para pinto e mÉtodo de inibiÇço de infecÇço por salmonella em pintos
UA91136C2 (ru) Системы, фармацевтическая композиция на его основе и способ ее применения
TW200727904A (en) Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine
DE602004012731D1 (de) Zubereitungen mit verzögerter freigabe enthaltend zink, und herstellung derselben
AR124399A2 (es) Formulaciones estables para la administración intratecal de iduranato-2-sulfatasa
UA33293U (ru) Способ лечения хронического эндометрита
AU2016219620A1 (en) Compositions and methods useful for treatment of respiratory illness

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.